Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Clin Exp Pharmacol Physiol ; 42(12): 1287-95, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26277051

RESUMEN

The present study aimed to investigate the antinociceptive and anti-inflammatory effects of the cyclic dipeptide cyclo-Gly-Pro (CGP) in mice. Antinociceptive activity was assessed by employing different pain models, such as formalin test, acetic acid-induced writhing, hot plate test, and carrageenan-induced hyperalgesia, in mice. The number of c-Fos-immunoreactive cells in the periaqueductal gray (PAG) was evaluated in CGP-treated mice. Anti-inflammatory activity was evaluated using paw oedema induced by carrageenan, compound 48/80, serotonin, and prostaglandin E2 (PGE2) and analyzed by plethysmometry. Quantitation of myeloperoxidase (MPO) in the paw was carried out to analyze the presence of neutrophils in the tissue. Intraperitoneal injection of CGP produced a significant inhibition in both neurogenic and inflammatory phases of formalin-induced pain. The antinociceptive effect of CGP, evaluated in the acetic acid-induced writhing test, was detected for up to 6 h after treatment. Further, in the hot plate test, antinociceptive behaviour was evoked by CGP, and this response was inhibited by naloxone. Animals treated with CGP did not present changes in motor performance. In CGP-treated mice there was an increase in the number of c-Fos-positive neurons in the periaqueductal gray. In another set of experiments, CGP attenuated the hyperalgesic response induced by carrageenan. Furthermore, CGP also reduced the carrageenan-increased MPO activity in paws. In addition, CGP also reduced the paw oedema evoked by compound 48/80, serotonin, and PGE2 . Taken together, these results may support a possible therapeutic application of the cyclic dipeptide cyclo-Gly-Pro toward alleviating nociception and damage caused by inflammation conditions.


Asunto(s)
Analgésicos/farmacología , Antiinflamatorios/farmacología , Conducta Animal/efectos de los fármacos , Nocicepción/efectos de los fármacos , Péptidos Cíclicos/farmacología , Proteínas Proto-Oncogénicas c-fos/metabolismo , Analgésicos/uso terapéutico , Animales , Antiinflamatorios/uso terapéutico , Regulación de la Expresión Génica/efectos de los fármacos , Hiperalgesia/tratamiento farmacológico , Inflamación/tratamiento farmacológico , Masculino , Ratones , Péptidos Cíclicos/uso terapéutico , Sustancia Gris Periacueductal/efectos de los fármacos , Sustancia Gris Periacueductal/metabolismo , Prueba de Desempeño de Rotación con Aceleración Constante
2.
Inflammation ; 37(5): 1575-87, 2014 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-24710701

RESUMEN

This study aimed at synthesizing the carvacrol propionate (CP) and evaluating its pharmacological profile. CP was obtained from carvacrol and propionyl chloride through an esterification reaction. Male Swiss mice were treated with CP (25, 50, or 100 mg/kg). We evaluated the analgesic effect, mechanical hyperalgesia, and anti-inflammatory effect. Pre-treatment with CP inhibited (p<0.01 and 0.001) the formalin-induced nociception in both phases. CP inhibited (p<0.05, 0.01, and 0.001) the development of mechanical hyperalgesia. CP was able to decrease the leukocyte recruitment (p<0.001) and the amount of TNF-α (p<0.001), IL-1ß (p<0.05), and protein leakage (p<0.01) into the pleural cavity. In addition, the paw edema was inhibited by CP (p<0.05, 0.01, and 0.001). The CP attenuates nociception, mechanical hyperalgesia, and inflammation, through an inhibition of cytokines.


Asunto(s)
Monoterpenos/síntesis química , Monoterpenos/farmacología , Propionatos/síntesis química , Propionatos/farmacología , Animales , Cimenos , Relación Dosis-Respuesta a Droga , Edema/tratamiento farmacológico , Edema/patología , Masculino , Ratones , Monoterpenos/uso terapéutico , Actividad Motora/efectos de los fármacos , Actividad Motora/fisiología , Dolor/tratamiento farmacológico , Dolor/patología , Propionatos/uso terapéutico , Distribución Aleatoria
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA